Thursday, November 19, 2020 10:09:34 PM
Looks like Gilead will lose some market share for Remdesivir. Perhaps this will finally prompt them to partner with Innovation Pharmaceuticals for Brilacidin.
https://www.cnbc.com/2020/11/19/coronavirus-who-tells-doctors-dont-use-gileads-remdesivir-splitting-with-fda.html?__source=androidappshare&fbclid=IwAR3z4fzJHQ1-U7LEK92Jfa-6ADdoY7GL8teKHO79HV9anxPyze-QCA5ghUU
https://www.cnbc.com/2020/11/19/coronavirus-who-tells-doctors-dont-use-gileads-remdesivir-splitting-with-fda.html?__source=androidappshare&fbclid=IwAR3z4fzJHQ1-U7LEK92Jfa-6ADdoY7GL8teKHO79HV9anxPyze-QCA5ghUU
Recent GILD News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/15/2026 08:13:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/15/2026 08:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2026 08:14:19 PM
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer • Business Wire • 06/24/2026 08:29:00 PM
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market • InvestorsHub NewsWire • 06/24/2026 01:00:00 PM
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market • GlobeNewswire Inc. • 06/24/2026 12:30:00 PM
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors • Business Wire • 06/23/2026 11:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/16/2026 10:02:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/16/2026 09:53:26 PM
- U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention • Business Wire • 06/15/2026 08:34:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/15/2026 08:30:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/15/2026 08:09:25 PM
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief • Business Wire • 06/12/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2026 10:35:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2026 10:34:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2026 10:32:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2026 10:31:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2026 10:29:51 PM
- National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership • Business Wire • 06/11/2026 12:30:00 PM
- Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment • Business Wire • 06/08/2026 08:35:00 PM
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study • Business Wire • 06/08/2026 08:30:00 PM
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa • Business Wire • 06/05/2026 07:00:00 AM
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline • Business Wire • 06/04/2026 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/02/2026 10:04:05 PM
- Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) • Business Wire • 06/02/2026 12:30:00 PM
